Forest gets exclusive US rights to Nycomed's Daxas
Forest Laboratories has licensed exclusive US marketing rights to fellow specialty drug company Nycomed's Daxas (roflumilast). Nycomed, which is developing the selective once-daily PDE4 enzyme inhibitor for symptomatic COPD, filed an NDA last month after completing four Phase III trials.
- Specialty Pharmaceuticals
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.